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Abstract: Background: In human failing hearts (HF) of different origin (coronary artery disease-CAD, dilated-DCM, re-
strictive and hypertrophic cardiomyopathy-OTHER), we investigated the active forms of Ca2+/calmodulin-dependent 
protein kinase IIδ (p-Thr287-CaMKIIδ, oxMet281/282-CaMKIIδ) and their role in phenotypes of the disease. Methods and 
results: Although basic diagnostic and clinical markers indicating the attenuated cardiac contractility and remodel-
ing were comparable in HF groups, CaMKIIδ-mediated axis was different. P-Thr287-CaMKIIδ was unaltered in CAD 
group, whereas it was upregulated in non-ischemic cardiomyopathic groups. No correlation between the upregu-
lated p-Thr287-CaMKIIδ and QT interval prolongation was detected. Unlike in DCM, oxMet281/282-CaMKIIδ did not differ 
among HF groups. Independently of CaMKIIδ phosphorylation/oxidation, activation of its downstreams-phosphol-
amban and cardiac myosin binding protein-C was significantly downregulated supporting both diminished cardiac 
lusitropy and inotropy in all hearts. Content of sarcoplasmic reticulum Ca2+-ATPase 2a in all HF was unchanged. 
Protein phosphatase1β was upregulated in CAD and DCM only, while 2A did not differ among groups. Conclusion: 
This is the first demonstration that the posttranslational activation of CaMKIIδ differs in HF depending on etiology. 
Lower levels of downstream molecular targets of CaMKIIδ do not correlate with either activation of CaMKIIδ or the 
expression of major protein phosphatases in the HF. Thus, it is unlikely that these mechanisms exclusively underlie 
failing of the heart. 
Keywords: Human heart failure, Ca2+/calmodulin-dependent protein kinase II, sarcoplasmic reticulum calcium 
handling, cardiac myosin binding protein-C
Introduction
Heart failure (HF) is a progressive cardiac dis-
ease ranging from stages which impair the 
patient’s quality of life and finally progress to a 
stage that is characterized by symptoms resis-
tant to treatment. HF can occur as a result of 
coronary artery disease (CAD), dilated cardio-
myopathy (DCM) and other hereditary and idio-
pathic causes [1]. In contrast to the most preva-
lent HF due to CAD, the age-adjusted preva-
lence of other forms of HF is lower (1:500 to 
1:2500) [1-3]. Regardless of etiology, all types 
of systolic HF are characterized by seriously 
impaired cardiac contractility leading into inad-
equate perfusion of organs. Great effort has 
been undertaken to understand the pathome- 
chanisms of systolic myocardial dysfunction. 
The abnormal Ca2+ cycling and defects in the 
sarcomeric proteins are proposed to be one of 
the crucial players in the adverse remodeling 
and dysfunction of the heart [4]. 
Ca2+/calmodulin-dependent protein kinase IIδ 
(CaMKIIδ) has emerged as an important Ca2+ 
handling protein regulating excitation-contrac-
tion coupling. Alterations in its activity have 
been proposed to exaggerate mishandling in 
Ca2+ homeostasis, and thereby underlie the de- 
pressed cardiac contractile function and arrhy- 
thmogenesis [5, 6]. Overactivation of CaMKIIδ 
can arise from its capability to undergo the vari-
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ous posttranslational modifications, including 
autophosphorylation (pThr287-CaMKIIδ) and oxi-
dation (oxMet281/282-CaMKIIδ) due to oxidative 
stress [7]. As CaMKIIδ phosphorylates a wide 
variety of proteins involved in the regulation of 
both Ca2+ handling (phospholamban-PLN), and 
contractile proteins (cardiac myosin binding 
protein-C-cMyBP-C), this protein kinase might 
be an interesting target in the management of 
HF treatment [8]. In fact, it has been previously 
reported that in failing hearts, sarcoplasmic 
reticulum (SR) Ca2+ uptake is significantly re- 
duced due to the inhibitory effects of PLN on 
SERCA2a [9, 10]. This may occur as a result of 
a decreased activity/expression of SERCA2a 
[11] or a higher expression of PLN [12, 13]. In 
addition to Ca2+ dysregulation, attenuation of 
cMyBP-C function, which serves as a regulatory 
and structural protein of the sarcomere, due to 
its dephosphorylation and subsequent degra-
dation of cMyBP-C is associated with the dimin-
ished cardiac contractile function and poor 
prognosis of patients with HF [14]. However, it 
is not known if the above-mentioned link involv-
ing SR Ca2+ proteins, cMyBP-C and CaMKIIδ, as 
a central signal-transducing element, is altered 
depending on the certain type of systolic ven-
tricular dysfunction. Therefore, the objective of 
this study was to provide a comprehensive 
analysis of the posttranslational activation of 
CaMKIIδ and if it is associated with the altera-
tions of downstream target proteins in the SR 
and sarcomere in human failing heart samples. 
We also investigated a potential role of protein 
phosphatases PP1 and PP2A counterbalanc- 
ing the effects of CaMKIIδ and its downstream 
proteins [15]. As CaMKIIδ has been suggested 
as a pro-arrhythmogenic marker [16, 17], and 
arrhythmias are a common complication of HF 
[18], therefore we also analyzed a correlation 
between the levels of the active forms of 
CaMKIIδ and QT interval duration.
Methods
Study design
All procedures were in accordance with ethical 
standards for human experiments based on 
Heslinki declaration. All experiments were ap- 
proved by national and institutional ethical 
commissions (statement no. IK-NP-0021-24/ 
1426/14 and NUSCH EK 126/180509). Sam- 
ples of left ventricles were obtained from ex- 
planted hearts of patients with diagnosed ter-
minal stadium of HF (NYHA III-IV) and reduced 
left ventricle ejection fraction (LVEF<25%). We 
employed the failing hearts due to coronary 
artery disease (CAD, n=6), dilated cardiomyop-
athy (DCM, n=10), and other cardiomyopathies 
being either restrictive or hypertrophied cardio-
myopathy (OTHER, n=6). All patients underwent 
echocardiographical, hemodynamical and bio-
chemical examination before transplantation. 
Additionally, the HF pharmacotherapy was ana-
lyzed from the last medical records. Samples of 
left ventricles from healthy donor patients (C, 
n=4), whose hearts cannot have been used for 
transplantation from various medical reasons 
(CMV infection, size/donor recipient mismatch, 
major damage during procedure), served as a 
control group. Tissues from the walls of left 
ventricles have been harvested in the time of 
explanation avoiding the scared, fibrotic and 
adipose tissues. They were afterwards rinsed, 
dried and snap-frozen in liquid nitrogen until 
further processing.
Immunoblotting
The samples of left ventricles were processed 
for the immunoblotting analysis based on our 
standard laboratory protocol for SDS-PAGE and 
Western Blotting [19]. Proteins were trans-
ferred on PVDF membranes (Immobilon-P, EMD 
Millipore, USA) and incubated with primary anti-
bodies against p-Thr287-CaMKII (Cell Signaling, 
USA), oxMet281/282-CaMKII (EMD Millipore, USA), 
total CaMKIIδ (Santa Cruz, USA), p-Thr17-PLN 
(Badrilla, UK), p-Ser16-PLN (Badrilla, UK), total 
PLN (Badrilla, UK), p-Ser282(284)-cMyBP-C (Enzo, 
USA), total cMyBP-C (Santa Cruz, USA), total 
SERCA2a (Badrilla, UK), PP1β (Abcam, USA) 
and PP2A (Sigma-Aldrich, USA). Afterwards, the 
incubation with HRP-conjugated secondary 
antibodies, donkey anti-rabbit IgG (GE Health- 
care Life Sciences, UK) and rabbit anti-goat IgG 
(Sigma-Aldrich, USA) was performed. Signals 
were detected by enhanced chemiluminiscen- 
ce (Crescendo Luminata, EMD Millipore, USA) 
and chemiluminiscence imaging system (my- 
ECL imager, Thermo Scientific, USA). Total pro-
tein staining with Coomasive Brilliant Blue R- 
250 or Reactive Brown 10B evaluated by scan-
ning densitometry was used as the loading con-
trol as a substitution to the housekeeping pro-
tein immunodetection [20-22]. Intensity of a 
particular protein band was compared to a 
whole lane. 
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Statistical analysis
The results are expressed as means ± stan-
dard error of means (S.E.M.), unless stated oth-
erwise. One-way ANOVA analysis with Newman-
Keuls and Tukey’s post-hoc tests and two-tailed 
unpaired Student’s t-test were used for evalua-
tion of group differences in variables with nor-
mal distribution. In case of the non-normal dis-
tribution, a Man-Whitney’s analysis was used. 
Correlation between biochemical parameters, 
QT duration or N-terminal pro-B type natriuretic 
peptide (NT-proBNP) and the levels of certain 
proteins was analyzed by Pearson’s test. All 
analyses were performed with GraphPad Prism 
6.00 for Windows (GraphPad Software, USA). 
Differences between groups were considered 
significant when P<0.05.
Results
Characteristics of study subjects
A summary of the main pre-transplant data of 
the study subjects are presented in Table 1. All 
patients irrespective of the etiology of HF were 
in either NYHA III or IV class. Among the HF 
groups, there were no significant differences in 
neither of the values of left ventricular ejection 
fraction (LVEF), parameters of cardiac remodel-
ing (the size of left and right end-diastolic ven-
tricular diameters-LVEDD, RVEDD), markers of 
pulmonary hypertension (systolic and diastolic 
pulmonary pressures-sPAP, dPAP) nor NT-pro- 
BNP, a common biochemical marker of HF. HF 
patients were treated at least with ACE inhibi-
tors or AT1R-blockers, beta-blockers and diuret-
ics. The control subjects were treated with the 
infusion of noradrenaline and dopamine and 
fluid balance was maintained with desmopres-
sin and hydroxyethyl starch, an intravenous col-
loid volume expander. They presented pre-
served systolic/diastolic function. No metabo- 
lic disorders were diagnosed in the study sub- 
jects.
Posttranslationally modified forms of CaMKIIδ 
in end-stage human HF show no association 
with the QT interval duration 
Western blot analysis of the posttranslationally 
modified forms of CaMKIIδ by phosphorylation 
at Thr287 and oxidation at Met281/282 is 
shown in Figures 1, 2.
The content of p-Thr287-CaMKIIδ in the group of 
CAD did not differ from the values of the control 
subjects. On the other hand, in all cardiomyop-
athic groups of HF, the expression of p-Thr287-
CaMKIIδ was significantly increased as com-
pared with the control hearts and CAD (Figures 
1, 2A). Of note, the levels of oxMet281/282-Ca- 
MKIIδ did not differ among HF group. However, 
by using Student’s t-test, significantly lower ex- 
pression of oxMet281/282-CaMKIIδ was observed 
in the DCM as compared to control group 
(Figures 1, 2B). This is the first analysis of the 
oxidized form of this protein kinase in human 
end-stage HF. 
Table 1. Echocardiographic, hemodynamic and biochemical parameters of probands
 Controls CAD DCM OTHER
RCM HCM
Age (years) 30 ± 5 52 ± 4 47 ± 3 47 ± 6 60 ± 4
LVEF (%) n.a. 21 ± 1 18 ± 1 34 ± 8 30 ± 5
LVEDD (mm) n.a. 75 ± 4 72 ± 3 60 ± 3 59 ± 1
RVEDD (mm) n.a. 34 ± 3 35 ± 1 33 ± 1 n.a.
QT (s) n.a. 0.42 ± 0.01 0.41 ± 0.02 0.44 ± 0.02 n.a.
sPAP (mm Hg) n.a. 44 ± 7 53 ± 5 52 ± 5 45 ± 6
dPAP (mm Hg) n.a. 21 ± 4 27 ± 3 28 ± 3 21 ± 2
CI (dm-3·min-1·m-2) n.a. 2.2 ± 0.1 1.8 ± 0.1 1.8 ± 0.2 n.a.
NT-proBNP (ng·dm-3) n.a. 3541 ± 1035 6571 ± 1682 3394 ± 1007 10124 ± 4152
Creatine kinase (µkat·dm-3) 3.09 ± 0.92 1.18 ± 0.26 1.17 ± 0.21 1.08 ± 0.47 0.97 ± 0.21
End-stage HF groups of ischemic and non-ischemic origin did not significantly differ in neither echocardiographic nor hemody-
namic parameters. CAD-coronary artery disease; DCM-dilated cardiomyopathy; RCM-restrictive cardiomyopathy; HCM-hypertro-
phied cardiomyopathy. LVEF-left ventricular ejection fraction; LVEDD-left ventricular end-diastolic diameter; RVEDD-right ventric-
ular end-diastolic diameter; QT-QT interval; sPAP-systolic pulmonary artery pressure; dPAP-diastolic pulmonary artery pressure; 
CI-cardiac index; NT-proBNP-N-terminal pro-B type natriuretic peptide. Data are expressed as the means ± SEM.
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The total CaMKIIδ was comparable in all HF 
groups and did not differ from the values of 
controls (Figures 1, 2C). Thus, the ratio of both 
p-Thr287/total CaMKIIδ and oxMet281/282-Ca- 
MKIIδ/total CaMKIIδ mimicked the pattern of 
diseased groups indicating that PKA does not 
substitute a role of CaMKIIδ to maintain the 
function of PLN (Figures 1, 3B). The expression 
of the total PLN (Figures 1, 3C) was unchanged 
in the HF groups, thereby the ratio of both 
Figure 1. Representative blots of evaluated proteins in control and human fail-
ing hearts. Total CaMKIIδ-total Ca2+/calmodulin-dependent protein kinase 2δ; 
p-Thr287-CaMKIIδ-phospho-Thr287-Ca2+/calmodulin-dependent protein kinase 
2δ; ox-Met281/282-CaMKIIδ-oxidized-Met281/282-Ca2+/calmodulin-dependent pro-
tein kinase 2δ; total PLN-total phospholamban; p-Thr17-PLN-phospho-Thr17-
phospholamban; p-Ser16-PLN-phospho-Ser16-phospholamban; SERCA2a-sar-
coplasmic/endoplasmic reticulum Ca2+-ATPase; total cMyBP-C-total cardiac 
myosin-binding protein C; p-Ser284-cMyBP-C-phospho-Ser284-cardiac myosin-
binding protein C; PP1β-protein phosphatase 1β; PP2A-protein phosphatase 
2A.
changes of the particular 
posttranslational modifica-
tions (Figures 1, 2D, 2E). 
QT interval prolongation is 
known as a predisposing 
factor for increased ventricu-
lar arrhythmia risk and a 
higher activity and/or expres-
sion of CaMKIIδ has been 
associated with arrhythmia 
triggering [23, 24]. Therefore 
in the groups of HF with the 
altered expression of post-
translationally modified form 
of CaMKIIδ (DCM, OTHER), a 
potential correlation between 
the content of phosphorylat-
ed form and prolongation of 
QT interval was analyzed. 
However, we did not identify 
any link between p-Thr287-
CaMKIIδ and the prolonga-
tion of QT interval (Figures 1, 
2F). 
Regulation of SR Ca2+ uptake 
in end-stage human HF 
As SR Ca2+ cycling is known 
to be diminished in HF [25] 
and CaMKII activates certain 
SR proteins [26] we further 
analyzed p-Thr17-PLN, a down-
stream of this protein kinase, 
and SERCA2a. In spite of the 
different state of the phos-
phorylation of CaMKIIδ in the 
particular HF types (ischemic 
vs. non-ischemic) (Figures 1, 
2A), the levels of p-Thr17-PLN 
were greatly downregulated 
in all HF groups in compari-
son to non-failing hearts 
(Figures 1, 3A). Likewise, 
PKA-dependent phosphoryla-
tion of PLN at Ser16 residue 
was decreased and there 
was no difference among the 
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p-Thr17-PLN/total PLN and p-Ser16-PLN/total 
PLN showed the same pattern as the respec-
tive active forms of this protein (Figures 1, 3D, 
3E). These data, as general characteristics of 
diastolic dysfunction, indicates no important 
role of the expression of either of active form of 
the upstream kinase in terminal HF. 
Non-phosphorylated form of PLN produces 
inhibitory effects on SERCA2a activity and 
restricts Ca2+ filling back into the SR [27, 28]. 
Therefore, we estimated a ratio between the 
total PLN and SERCA2a. Similarly to the total 
PLN, the levels of total SERCA2a were unchan- 
ged in all HF groups when compared to control 
Figure 2. Phosphorylation (p-Thr287-CaMKIIδ) and oxidation (oxMet281/282-CaMKIIδ) of CaMKIIδ in different types 
of terminal human HF. (A) Levels of p-Thr287-CaMKIIδ; (B) Content of oxMet281/282-CaMKIIδ; (C) Expression of total 
CaMKIIδ; (D) Ratio of phosphorylated to total CaMKIIδ; (E) Ratio of oxidized to total CaMKIIδ; (F) Comparison be-
tween QT interval duration and phosphorylation of CaMKIIδ (n=12). Data for (A-E) are expressed as the means ± 
S.E.M. n=4-10 hearts per group. *P<0.05 vs. control hearts. 
Figure 3. CaMKIIδ-dependent (p-
Thr17-PLN) and PKA-dependent phos-
phorylation (p-Ser16-PLN) of PLN in 
human failing hearts. (A) Expression 
of p-Thr17-PLN; (B) Expression of p-
Ser16-PLN; (C) Expression of total PLN; 
(D) Ratio of p-Thr17-PLN to total PLN; 
(E) Ratio of p-Ser16-PLN to total PLN. 
Data for (A-E) are expressed as the 
means ± S.E.M. n=4-10 hearts per 
group. *P<0.05 vs. control hearts.
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group (Figures 1, 4A). Accordingly, no signifi-
cant changes were found in the PLN/SERCA2a 
ratio in HF groups as compared with non-failing 
hearts (Figures 1, 4B). 
Cardiac MyBP-C in human HF
In addition to the altered Ca2+ cycling, the res- 
ponse of the contractile proteins is diminished 
in HF [29]. Therefore, we evaluated expression 
of total cMyBP-C and its phosphorylated form 
at Ser284. Unlike the expression of the total 
protein (Figure 5B), the levels of p-Ser284-cMy- 
BP-C were significantly downregulated in all HF 
groups regardless the expression of particular 
posttranslationally modified forms of CaMKIIδ 
(Figures 1, 5A, 5C). These results indicate 
serious systolic dysfunction in HF and similarly 
to the status of p-Thr17-PLN propose no role of 
the levels of the active forms of CaMKIIδ in this 
context. 
To further expand the knowledge about this 
active form of cMyBP-C in end-stage human HF, 
a correlation between the serum NT-proBNP 
and p-Ser284-cMyBP-C was evaluated. Interest- 
ingly, the levels of NT-proBNP positively corre-
Figure 4. Content of SERCA2a in human failing hearts and ratio of total PLN to SERCA2a. (A) Expression of SERCA2a. 
(B) Ratio of total PLN to SERCA2a. Values for (A) and (B) are expressed as the means ± S.E.M. n=4-10 hearts per 
group.
Figure 5. Expression and phosphorylation of cMyBP-C in human failing hearts. (A) Expression of p-Ser284-cMyBP-C; 
(B) Content of total cMyBP-C; (C) Ratio of p-Ser284-cMyBP-C to total protein. Values for (A-C) are expressed as the 
means ± S.E.M. n=4-10 hearts per group. *P<0.05 vs. control hearts.
Figure 6. Correlation between the expression of p-
Ser284-cMyBP-C and marker of volume overload and 
myocyte stretch NT-proBNP in failing hearts. n=13 
hearts. Correlation was considered as positively sig-
nificant (P=0.0181). 
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lated with the levels of p-Ser284-cMyBP-C in the 
HF groups (Figures 1, 6). This may indicate a 
compensatory increase in cMyBP-C phosphory-
lation in response to increased myocyte stretch 
documented by the higher levels of NT-proBNP. 
Modulation of protein phosphorylation status 
by protein phosphatases in failing hearts
We also analyzed certain protein phosphatases 
which counterbalance the phosphorylation of 
PLN, cMyBP-C and CaMKIIδ itself. Indeed, two 
major isoforms of protein phosphatases in 
human myocardium, PP1 subunit β (PP1β) and 
PP2A were investigated. PP1β, proposed to 
dephosphorylate the most of PLN as well as 
cMyBP-C [30], was increased in the CAD and 
DCM group but not in other cardiomypathic 
groups (Figures 1, 7A). PP2A sharing similar 
catalytic sites with PP1 [31, 32] proposed also 
to dephosphorylate cMyBP-C [33, 34] and most 
of CaMKII in cytosolic and membrane fraction 
[35] did not differ among the diseased groups 
nor in comparison with control healthy hearts 
(Figures 1, 7B).
Discussion
In the present comprehensive study we have 
shown that the levels of both active, posttrans-
lationally modified forms of CaMKIIδ, p-Thr287-
CaMKIIδ and oxMet281/282-CaMKIIδ in failing 
hearts due to CAD were comparable to those of 
healthy hearts. On the other hand, in HF of non-
ischemic origin (DCM, RCM and HCM), p-Thr287-
CaMKIIδ was upregulated whereas expression 
of oxMet281/282-CaMKIIδ was unchanged. Re- 
gardless the levels of these active forms of the 
kinase, the downstream targets of CaMKIIδ, 
such as p-Thr17-PLN or p-Ser284-cMyBP-C were 
Figure 7. Expression of protein phosphatases PP1β and PP2A in left ventricles of various types of human heart 
failure. (A) Expression of PP1β; (B) Expression of PP2A. Values for (A) and (B) are expressed as the means ± S.E.M. 
n=4-10 hearts per group. *P<0.05 vs. control hearts.
Table 2. Expression of evaluated proteins in 
left ventricles of human failing hearts of dif-
ferent origin
Proteins CAD DCM OTHER
Total CaMKIIδ ≈ ≈ ≈
p-Thr287-CaMKIIδ ≈ ↑ ↑
ox-Met281/282-CaMKIIδ ≈ ↓ ≈
Total PLN ≈ ≈ ≈
p-Thr17-PLN ↓ ↓ ↓
p-Ser16-PLN ↓ ↓ ↓
SERCA2a ≈ ≈ ≈
Total cMyBP-C ≈ ≈ ≈
p-Ser284-cMyBP-C ↓ ↓ ↓
PP1β ↑ ↑ ≈
PP2A ≈ ≈ ≈
Table summarizes protein expression detected by 
immunoblot analysis between particular HF groups: 
CAD-coronary artery disease; DCM-dilated cardiomyopa-
thy; RCM-restrictive cardiomyopathy; HCM-hypertrophied 
cardiomyopathy and control group. Total CaMKIIδ, 
p-Thr286-CaMKIIδ, ox-Met281/282-CaMKIIδ-total, phospho-
Thr286 and oxidized-Met281/282-Ca2+/calmodulin-dependent 
protein kinase IIδ; total PLN, p-Thr17-PLN, p-Ser16-PLN-
total, phospho-Thr17 and phospho-Ser16-phospholam-
ban; SERCA2a-sarcoplasmic/endoplasmic reticulum 
Ca2+-ATPase; total cMyBP-C, p-Ser284-cMyBP-C-total and 
phospho-Ser284-cardiac myosin-binding protein C; PP1β-
protein phosphatase 1β; PP2A-protein phosphatase 2A. 
(≈)-no difference in expression; (↑)-significantly increased 
expression in comparison to control group; (↓)-significant-
ly decreased expression in comparison to controls. Differ-
ences between the groups were evaluated by ANOVA test 
and considered significant when P<0.05. 
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significantly downregulated in all HF types. 
Evaluation of protein phosphatases revealed 
the upregulated content of PP1β in CAD and 
DCM but not in other types of HF. Expression 
of PP2A in failing hearts did not differ of the 
levels of controls. Thus, this study employing 
the samples of various types of HF (both of a 
high and low incidence) provides the first 
demonstration that i) the oxidative activation 
of CaMKIIδ does not go hand in hand with its 
activation through phosphorylation, ii) CaMKIIδ 
activation through phosphorylation and oxida-
tion differs depending on the etiology of HF, iii) 
the lower phosphorylation of the downstream 
proteins indicating diminished inotropy and 
lusitropy in these diseased hearts is not 
paralleled with either active forms of CaMKIIδ 
or with the expression of the main cardiac 
protein phosphatases (Table 2).
Under physiological conditions, the activation 
of CaMKII in heart is mainly regulated by auto-
phosphorylation in the presence of Ca2+/CaM 
[36]. This mechanism allows the kinase to acti-
vate various Ca2+-sensitive proteins to ensure 
proper Ca2+ handling, including proteins regu-
lating the function of the sarcoplasmic reticu-
lum and sarcomere [37-39]. Therefore, the 
observed higher activation state of CaMKIIδ 
and Ca2+ mishandling may contribute to the dis-
turbances in contraction and relaxation in HF 
[40]. Considering these deleterious effects of 
the overactivated protein kinase, increased p- 
Thr287-CaMKIIδ could be expected in the failing 
hearts. However, in spite of this logical hypoth-
esis, data shown in this study as well as in 
others [41, 42] are unequivocal. In fact, all HF 
hearts characterized by depressed cardiac 
contractility and remodeling have shown the 
different pattern of oxidation and phosphoryla-
tion of CaMKIIδ. Moreover, the pattern of 
changes in the oxidative activation of the 
kinase did not mimic the changes in phosphory-
lation and vice versa. Interestingly, in spite of 
this observation the markers of HF such as 
NT-proBNP, pulmonary arterial pressures, EF or 
cardiac indices did not differ among the types 
of HF.
So far published papers have mainly been deal-
ing with CaMKII in human HF of a higher inci-
dence. In study of Miyamoto et al. [43], in DCM, 
the increased phosphorylation of CaMKII has 
been reported what is in line with our data. On 
the other hand, similarly to Fisher et al [42] the 
ratio of the phosphorylated form/total protein 
kinase has not indicated the changes among 
the groups. In another study, the activity of Ca- 
MKII measured by enzymatic assay was found 
to be increased in DCM while unchanged in 
CAD [41]. By predicting a linear link between 
phosphorylation and catalytic activity of the 
kinase this observation is in line with results 
reported in this study. In the present study, we 
have extended the current knowledge on the 
activation of CaMKIIδ and reported for the first 
time the content of p-Thr287-CaMKIIδ being also 
upregulated in HF types of a lower incidence. It 
has been suggested that the overactivated/
hyperphosphorylated CaMKII is associated 
with electrical instability along with contractile 
dysfunction [19, 42, 44]. However, we have 
been unable to found any correlation between 
p-Thr287-CaMKIIδ expression and the duration 
of QT interval in the HF groups of non-ischemic 
origin which exerted the higher phosphoryla-
tion of this protein kinase.
In addition to phosphorylation, CaMKIIδ can 
undergo other posttraslational modifications 
[7]. In the presence of oxidative stress, which is 
commonly observed in HF [45], the activation 
of CaMKIIδ through oxidation might be of a 
great relevance thereby suggesting the levels 
of oxMet281/282-CaMKIIδ being increased in our 
samples of human HF. Of note, the increased 
levels of oxMet281/282-CaMKIIδ have been 
shown to underlie electrical remodeling and 
hypertrophy in cardiac myocytes and isoprena-
line-treated rats [46, 47]. Surprisingly, no 
changes in the expression of oxMet281/282-
CaMKIIδ were found among HF groups. 
However, while comparing DCM and control 
group, oxMet281/282-CaMKIIδ was found to be 
decreased in the diseased hearts. It has been 
proposed that methionine residues at 281/282 
can undergo oxidation by superoxide produced 
by NADPH oxidases what leads into the kinase 
activation [48, 49]. Another enzyme, methio-
nine sulfoxide reductase A is able to reverse 
this effect and thereby decrease pro-oxidant 
potential of the kinase [48]. It would be inter-
esting to measure the activity of this enzyme; 
however, at the time of performing the study it 
was impossible due to the unavailability of 
assay and antibody. Thus, the aforementioned 
data indicate that a role of CaMKIIδ including 
its posttranslational forms should be carefully 
investigated and the particular etiology of HF 
should be taken into account while assessing 
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its involvement in the pathologic mechanisms 
of the disease. Of note, in our recent study, we 
have shown that both p-Thr287-CaMKIIδ and 
oxMet281/282-CaMKIIδ are not elevated, rather 
markedly decreased in the late phase of reper-
fusion of previously ischemic hearts which 
experienced contractile dysfunction and higher 
oxidative stress [19]. 
CaMKIIδ is one of critical proteins regulating 
proper Ca2+ cycling. For instance, by phosphory-
lation of PLN at Thr17 it relieves the inhibitory 
effects on SERCA2a and thereby mediates lusi-
tropic effects [50]. Since HF is characterized 
by significantly abolished cardiac contractility 
and relaxation we have hypothesized CaMKIIδ-
dependent phosphorylation of PLN being de- 
creased. In agreement with this hypothesis, the 
expression of CaMKIIδ-phosphorylated form 
of p-Thr17-PLN was decreased to almost non-
detectable levels in all HF groups. Similarly to 
our study, Dash et al. [12] and Miyamoto et al. 
[43] have also reported CaMKII-mediated phos-
phorylation of PLN being decreased in DCM. 
The content of p-Thr17-PLN was parallel with the 
levels of p-Ser16-PLN regulated by PKA. Addi- 
tionally, we have shown that SERCA2a levels 
did not differ among the groups what is in 
agreement with some previous studies [11, 
51]. On the other hand, downregulation of 
SERCA2a in heart failure resulting from DCM 
has also been reported [12, 52]. The expres-
sion of the ratio of total PLN to SERCA2a was 
unaltered in all diseased groups. The levels of 
non-phosphorylated PLN have been suggested 
to act as a marker of decreased SERCA2a 
pumping activity [53]. However, our data and of 
others [39, 43, 54] do support the role of phos-
phorylated PLN rather than the non-phosphory-
lated protein in diminished Ca2+ SR handling in 
HF. 
CaMKIIδ is also known to directly phosphory-
late some proteins of contractile apparatus 
and thereby regulates cardiac contractility in- 
dependently of Ca2+ cycling modulation. In fact, 
it phosphorylates cMyBP-C, regulates actin-
myosin cross-bridging, and controls force gen-
eration within the sarcomere [29]. Recently, 
cMyBP-C has been proposed to serve as a no-
vel biomarker of cardiac injury [14, 55]. De- 
phosphorylation and subsequent degradation 
of this protein may indicate cardiac dysfunction 
and HF [56, 57]. Likewise, several gene muta-
tions of this protein have been reported in CAD, 
DCM and HCM [58, 59]. 17 phosphorylation 
sites of cMyBP-C being phosphorylated by four 
various kinases have been identified so far; 
however, Ser282 residue (Ser284 in humans), 
which can be phosphorylated by CaMKII [60], 
is the most frequent target of phosphorylation 
in vivo [61]. Here, we have shown that phos-
phorylation of Ser284 residue was significantly 
downregulated while the total protein was unal-
tered in all HF groups. In support, other studies 
dealing with genetic mutations promoting car-
diac dysfunction have reported total cMyBP-C 
being downregulated [59]. In context with 
p-Thr287-CaMKIIδ, these observations open 
several questions. Similarly to p-Thr17-PLN, 
p-Ser284-cMyBP-C was decreased independent-
ly of the phosphorylation/oxidation of the 
upstream protein kinase CaMKIIδ. However, as 
indicated above, it should be mentioned that 
the Ser284 residue of cMyBP-C can also be 
phosphorylated by some other protein kinases 
such as PKA, PKC or ribosomal S6 kinase [29]. 
Nevertheless, the phosphorylation of Ser284 
mediated by CaMKII seems to play an impor-
tant role because its inhibition resulted in the 
decreased phosphorylation of cMyBP-C [62, 
63].
As the ability of the kinase to phosphorylate the 
proteins is counterbalanced by phosphatases 
we investigated the expression levels of main 
cardiac protein phosphatases PP1 and PP2A. 
The PP1 has been proposed to serve as a nega-
tive regulator of cardiac function. It is able to 
dephosphorylate substrates of CaMKIIδ and 
thus may play an important role in gradual 
blunting of heart function during the develop-
ment of HF [15, 64]. In this and in previously 
published studies [30, 43, 65], the expression 
of β subunit of PP1 was increased only in CAD 
and DCM failing hearts. Interestingly, the most 
abundant PP, PP2A did not differ among the HF 
groups and was comparable to the value of 
controls. The data about PP2A are controver-
sial. The increased mRNA levels have been 
reported in DCM [43], while the protein content 
of this phosphatase was unchanged [66] sup-
porting the findings of our current study. 
Although this study has reported several novel 
findings and raised some new questions, there 
are few limitations. Firstly, the conclusions are 
based on proteomic data only. Nevertheless, 
we aimed to investigate an association between 
certain posttranslational modifications of Ca- 
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MKIIδ and its downstream proteins, with cardi-
ac function of all known types of HF. Secondly, 
phosphorylation status of proteins can be 
affected by certain drugs, however, by assum-
ing that all HF patients were given the standard, 
almost the same therapy, this is unlikely to 
influence our present data. 
Conclusion
In failing hearts of ischemic and non-ischemic 
origin, not differing in any main diagnostic char-
acteristics, we have detected a different phos-
phorylation and oxidation status of CaMKIIδ. 
The changes in posttranslational status of the 
kinase have not reflected the phosphorylation 
of its downstream targets neither in p-Ser284-
cMyBP-C nor p-Thr17-PLN which, however were 
significantly downregulated and thereby could 
underlie the diminished cardiac contractile and 
relaxation function in HF. By investigating a link 
between the duration of the QT interval and the 
posttranslationally modified levels of CaMKIIδ 
we have been unable to confirm that the altered 
activation of CaMKIIδ promotes pro-arrhythmo-
genic environment. Thus, the assessment of a 
role of CaMKIIδ, its active forms and potential 
consequences on cardiac function in particular 
forms of HF needs more detailed investiga- 
tions. 
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